Incyte Corp. (INCY): Price-to-Revenue Ratio

Brandmark of Incyte Pharma (INCY)

Incyte Corporation (INCY) seeks to protect its hematology market share from generics by updating its drug formulas. Business growth is based on patents that enable the mass production of high-cost, high-margin medications. Revenues from Jakafi fund new developments in oncology and dermatology. The price/sales ratio trend visualizes the market valuation, where the 4.10 indicator determines the metric's value at this time.

INCY Incyte Corporation P/S Multiple (07/04/2022 - 11/13/2026)

Incyte Corp. (INCY) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price incyte.com|INCY - Price Target Chart
- stock exchange capitalization data:
Market Value Incyte Corp.|INCY - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Incyte|INCY - Book Capitalization|Market Value to Equity Ratio incyte.com|INCY - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Incyte Corporation|INCY - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Incyte Pharma|INCY - Company Total Debt|Debt to Book Capital Incyte Corp.|INCY - Company Long-Term Debts|Company Short-Term Loans and Borrowings Incyte|Immediate Liquidity incyte.com
- earnings and multiples data:
INCY - Company Net Income|Expected Net Income Incyte Corporation|INCY - P/E Multiple|Forward P/E Multiple Incyte Corp|INCY - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Incyte Corp.|INCY - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Incyte|INCY - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months incyte.com|INCY - Earnings per share growth in current year|Projected earnings per share growth rate for next year Incyte Corporation
- issuer revenue and sales details:
INCY - Revenue and Sales Volume|Company Future Sales Volume incyte.com|INCY - Market Cap to Revenue|Market Cap to Future Revenue Ratio Incyte Corp.
Summary company analytics:incyte.com
Mass-produced product of Incyte Pharma

The P/S ratio determines the market value of one dollar of annual revenue, allowing for an assessment of the premium paid for a business regardless of current earnings. For Incyte Corporation (INCY), with its advanced R&D pipeline in JAK inhibitors and targeted therapy, this indicator reflects market expectations for future breakthroughs, making the historical P/S chart a key tool for analyzing the balance between innovative potential and asset valuation.

Competing companies

HCM - Price to Sales|Price-to-Revenue Ratio Nuvation Bio NUVB|Day One Biopharmaceuticals, Inc. - Price-to-Revenue Ratio|MNPR - Price-to-Revenue Ratio|Price to Sales Inhibrx Corp|IMAB: P/S Multiple|Price-to-Revenue Multiple fennecpharma.com FENC|Market Cap to Revenue HRTX|Price to Sales Nuvectis Pharma Inc. NVCT|Market Cap to Revenue CHRS (Coherus)|CRBP (Corbus Pharmaceuticals, Inc.) - Market Capitalization-to-Revenue Ratio|Cardiff Oncology - Market Cap to Revenue|Market Cap to Sales Volume BYSI (beyondspringpharma.com)|BioAtla Corp - P/S Multiple|Market Capitalization-to-Revenue Ratio LIXT (Lixte Biotechnology Holdings Inc.)|CTXR: P/S Multiple|Price to Sales Cellectar Corp (CLRB)|Price-to-Revenue Ratio BioLineRx Ltd.|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple kaziatherapeutics.com (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales cyclacel.com|GTHX: P/S Multiple|KRON - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Kintara|Market Cap to Revenue Ratio ONCT (Oncternal Corp)|P/S Multiple PRTG